The percentage of M1-type (CD80+CD11b+F4/80+) macrophages infiltrated in the residual tumours from the BP-based PPT and aCD47 combination treatment group was significantly higher than that in the control groups, suggesting that this combined therapy induced the polarisation of tumour-specific macrophages towards the M1 phenotype and thus altered the immunosuppressive status into a more permissive tumour microenvironment to promote tumour regression (Fig. 6a). Here, CD80 is linked to neoplasm.